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Abstract 
The purpose of this study was to prepare ginkgolide B (GB) lyophilized powder for injection with 
excellent appearance and stable quality through a formulation screening and by optimizing the 
freeze-drying process. Cremophor EL as a solubilizer, PEG 400 as a latent solvent and mannitol as 
an excipient were mixed to increase the solubility of GB in water of more than 18 times (about 
from 2.5×10-4 mol/L(0.106mg/ml) to 1.914 mg/ml). Formulation screening was conducted by 
orthogonal design where the content of GB in the solution before lyophilization (using external 
standard method of HPLC) and reconstitution time after lyophilization were the two evaluation 
indexes. The optimized formulations were GB in an amount of 2 mg/ml, Cremophor EL in an 
amount of 16% (v/v), PEG 400 in an amount of 9% (v/v), mannitol in an amount of 8% (w/v), and 
the solution pH of 6.5. Through 4 single factor experiments (GB adding order, preparation 
temperature of GB solution, adding amount and adsorption time of activated carbon), the 
preparation process of GB solution was confirmed. The glass transition temperature of maximally 
GB freeze-concentrated solution was -17.6℃  through the electric resistance method. GB 
lyophilized powder began to collapse at -14.0℃, and the fully collapse temperature was -13.0℃, 
which were determined by freeze-drying microscope. When the collapse temperature was 
determined, then the primary drying temperature was obtained. Thereby, the freeze-drying curve 
of GB lyophilized powder was initially identified. The freeze-drying process was optimized by 
orthogonal design, the qualified product appearance and residual moisture content were as two 
evaluation indexes. The optimized process parameters and process were: (1) shelf 
temperature,decreased from room temperature to -45.0℃ at 0.5 ℃/min in two hours; (2) shelf 
temperature increased from -45.0℃ to -25.0℃ at 0.1 ℃/min, maintaining 3 hours, and the 
chamber pressure held at 10 Pa; (3) shelf temperature was increased from -25.0℃ to -15.0℃ at 
0.1 ℃/min, maintaining 4 hours, and the chamber pressure held at 10 Pa; (4) shelf temperature 
Title Page
was increased from -15.0℃ to 20.0℃ at 1.0 ℃/min, maintaining 4 hours, and the chamber 
pressure was raised up to 80 Pa. In these lyophilization process conditions, the products complied 
with relevant provisions of the lyophilized powders for injection, meanwhile, the reproducibility 
was satisfactory. Post-freezing annealing had no significantly beneficial effects on shortening the 
freeze-drying cycle and improving the quality of GB lyophilized powder. 
Key words: Ginkgolide B, formulation screening, freeze-drying process optimization, collapse 
temperature 
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Abstract 8 
The purpose of this study was to prepare ginkgolide B (GB) lyophilized powder for injection with 9 
excellent appearance and stable quality through a formulation screening and by optimizing the 10 
freeze-drying process. Cremophor EL as a solubilizer, PEG 400 as a latent solvent and mannitol as 11 
an excipient were mixed to increase the solubility of GB in water of more than 18 times (about 12 
from 2.5×10-4 mol/L(0.106mg/ml) to 1.914 mg/ml). Formulation screening was conducted by 13 
orthogonal design where the content of GB in the solution before lyophilization (using external 14 
standard method of HPLC) and reconstitution time after lyophilization were the two evaluation 15 
indexes. The optimized formulations were GB in an amount of 2 mg/ml, Cremophor EL in an 16 
amount of 16% (v/v), PEG 400 in an amount of 9% (v/v), mannitol in an amount of 8% (w/v), and 17 
the solution pH of 6.5. Through 4 single factor experiments (GB adding order, preparation 18 
temperature of GB solution, adding amount and adsorption time of activated carbon), the 19 
preparation process of GB solution was confirmed. The glass transition temperature of maximally 20 
GB freeze-concentrated solution was -17.6℃  through the electric resistance method. GB 21 
lyophilized powder began to collapse at -14.0℃, and the fully collapse temperature was -13.0℃, 22 
which were determined by freeze-drying microscope. When the collapse temperature was 23 
determined, then the primary drying temperature was obtained. Thereby, the freeze-drying curve 24 
of GB lyophilized powder was initially identified. The freeze-drying process was optimized by 25 
orthogonal design, the qualified product appearance and residual moisture content were as two 26 
evaluation indexes. The optimized process parameters and process were: (1) shelf temperature, 27 
decreased from room temperature to -45.0℃ at 0.5 ℃/min in two hours; (2) shelf temperature 28 
increased from -45.0℃ to -25.0℃ at 0.1 ℃/min, maintaining 3 hours, and the chamber pressure 29 
held at 10 Pa; (3) shelf temperature was increased from -25.0℃ to -15.0℃ at 0.1 ℃/min, 30 
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maintaining 4 hours, and the chamber pressure held at 10 Pa; (4) shelf temperature was increased 1 
from -15.0℃ to 20.0℃ at 1.0 ℃/min, maintaining 4 hours, and the chamber pressure was raised 2 
up to 80 Pa. In these lyophilization process conditions, the products complied with relevant 3 
provisions of the lyophilized powders for injection, meanwhile, the reproducibility was 4 
satisfactory. Post-freezing annealing had no significantly beneficial effects on shortening the 5 
freeze-drying cycle and improving the quality of GB lyophilized powder. 6 
KEY WORDS: Ginkgolide B, formulation screening, freeze-drying process optimization, 7 
collapse temperature 8 
 9 
INTRODUCTION 10 
Ginkgo biloba is among the oldest living trees, with a long history of use in traditional 11 
Chinese medicine. In recent years, the extracts of ginkgo biloba leaf have been widely sold as 12 
herbal medications worldwide. The most unique components of the extracts are the terpene 13 
trilactones: ginkgolides and bilobalide. Ginkgolide B (GB) is one kind of ginkgolides, and it is the 14 
most potent inhibitor of the platelet-activating factor receptor (PAFR)（1）. PAFR is a highly active 15 
mediator in the human body and has been implicated in various disease states（2）. GB has been 16 
postulated to include improvement of memory, increased blood circulation, as well as beneficial 17 
effects to sufferers of Alzheimer's disease（3,4）and cisplatin-induced ototoxicity（5）. 18 
GB is a diterpene with a cage skeleton consisting of six five-membered rings (Fig.1): a 19 
spiro[4.4]-nonane carbocyclic ring, three lactones, and a tetrahydrofuran ring, with a relative 20 
molecular weight of 424.4 g/mol （6）. GB is a white crystal, and can be dissolved in acetone, 21 
ethanol, methanol, ethyl acetate, tetrahydrofuran, dioxane, acetic acid, trifluoroacetic acid, 22 
acetonitrile, pyridine as well as dimethyl sulfoxide, and slightly dissolved in ethyl ether and water 23 
(the solubility in water of 2.5×10-4 mol/L(0.106mg/ml)). GB cannot be dissolved in hexane, 24 
benzene, chloroform and carbon tetrachloride（7,8）. Under neutral or acidic conditions, all 25 
lactonic rings of GB are closed; under alkaline conditions (pH at 7.5 to 12), some lactonic rings 26 
are opened because of hydrolysis. If the alkalinity increases, the majority of lactonic rings are 27 
opened to form salts. However, the GB without hydrolysis is the biologically active form, this is 28 
one of the reasons why some GB formulations can not reach the expected clinical efficacy29 
（9,10）.Under physiological conditions, the lactonic rings of GB are partially hydrolyzed, the 30 
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original form only accounts for 34 percent at equilibrium（11）. 1 
Ginkgo biloba products are offered today in many different preparations sometimes without 2 
any kind of scientific background and control. However, in evidence-based medicine and all 3 
clinical investigations and treatments, ginkgo biloba should only be used in the form of 4 
standardized ginkgo biloba extracts (e.g. EGb 761®, LI 1370®) defined by a special composition 5 
and manufacturing process（12）. Since GB is poorly soluble in water and gastric fluid 6 
environment, resulting in low dissolution and bioavailability through oral administration, it limits 7 
the development of oral preparations to some extent（13）. Lyophilized formulations can be 8 
injected after reconstitution, so that higher bioavailability can be ensured（14）. Furthermore, the 9 
loss of the active ingredient is reduced during the freeze-drying production. In general, lyophilized 10 
formulations are easy to transport and long-term storage. In order to develop GB to lyophilized 11 
powder for injection, the a five step procedure  has been carried out in this paper: (1) solvent, 12 
surfactant, excipient and solution of PH screening for formulation; (2) process preparation: 13 
choosing GB API adding order, mixing temperature, added amount of active carbon and 14 
absorption time; (3) freeze-drying optimization of process parameters for freeze stage, primary 15 
drying stage and secondary drying stage; (4) Verification experiments of lyophilization process; (5) 16 
Effects of annealing on lyophilization rate and product quality. 17 
MATERIALS AND METHODS 18 
Materials 19 
GB (the purity≥98%) was purchased from Nanjing Dierge Medical and Technological Co., 20 
Ltd.(Jiangsu, China). Tween 80, Tween 20, Tween 40, Poloxamer 188, Cremophor El, glucose, 21 
lactose, mannitol, dextran20, sucrose and L-arginine were purchased from Aladdin Reagent 22 
Database Inc. (Shanghai, China), which were analytical grades. Methanol was obtained from 23 
Xingke Solvent Inc. (Shanghai, China), which was HPLC grade. Water for injection was supplied 24 
from GMP Training Center of China Pharmaceutical University.  25 
Formulation Screening of GB Lyophilized Powder for Injection 26 
Specification Determination 27 
Only several ginkgo biloba preparations were approved in China. On the basis of the ginkgo 28 
biloba injection produced by Chengdu Baiyu Pharmaceutical Co., Ltd.(Sichuan, China), each vial 29 
contains 2 mL solution and 10 mg terpene lactones as active pharmaceutical ingredient (API), in 30 
4 
 
which, GB probably accounts for thirty-four percent, being equal to 1.7 mg/mL. Therefore, each 1 
vial contained 2 mL GB solution after reconstitution in this study, and the concentration of GB 2 
was 2.0 mg/mL. 3 
Establishing a Standard Curve between Concentrations and Peak Areas of GB  4 
GB standards were accurately weighed and placed in a volumetric flask, then dissolved with 5 
methyl alcohol. The obtained solution was diluted by methyl alcohol to prepare standard solutions 6 
with different concentrations, such as 0.5×103 mg/L, 1×103 mg/L, 2×103 mg/L, 4×103 mg/L, 6×103 7 
mg/L, then the contents of GB were determined with HPLC (Shimadzu Co., Ltd, China). The 8 
chromatographic conditions: the column was Agilent ZORBAX SB-C18 (4.6×150 mm, 5 μm), the 9 
column temperature was 25℃, the mobile phase was methanol-water (50:50), the velocity of flow 10 
was 1.0 mL/min, the detection wavelength was 220 nm, and the injection volume was 20 μL. 11 
The concentrations of GB and their correspondent peak area data were shown in Table 1, the 12 
standard curve was shown in Fig. 2. The results showed that from 0.5×103 mg/L to 6×103 mg/L, 13 
and three experiments were repeated at each concentration to get the standard deviation of peak 14 
area. As a result, the linear relationship between concentrations and peak areas was good. The 15 
sampling precision test was done as follows: the reference solution (the concentration of 4×103 16 
mg/L) was sampled six times, and the peak areas were recorded, and RSD was 0.15% by 17 
calculation. 18 
Table 1 GB standard curve data 19 
GB con. 
/mg·L-1 
500 1000 2000 3000 4000 5000 6000 
Peak areas 
291028±
1896 
612131±
2130 
1207230±
4213 
1793174±
6472 
2458279±
8745 
3075164±
11824 
359107
7±1465
8 
Regression 
equation 
y = 606.49x -1634.4, R² = 0.9993（n=7） 
Note: “n=7” means the number of GB concentrations to fit the regression equation of 7. 20 
 21 
Solvent Selection 22 
The most commonly used solvent in lyophilized powder for injection is water, but GB is 23 
poorly soluble in it. Therefore, mixed solvents were considered. Among solvents with ability to 24 
dissolve GB, ethyl alcohol, propylene glycol, glycerin, PEG 200 and PEG 400 had higher safety, 25 
which could be mixed with water to form co-solvents. It was found that the solubility to GB of the 26 
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co-solvents increased with their increased volume concentration. However, when volume 1 
concentrations of ethyl alcohol, propylene glycol, glycerin, PEG 200 were above 10 percent, the 2 
frozen solid could easily spray during primary drying. Because their melting point were relatively 3 
low, which were hard to be fully frozen. Only PEG 400 had relatively high melting point, and the 4 
above phenomenon did not easily happen. So PEG 400 and water for injection as the co-solvent 5 
was chosen. 6 
Solubilization Method Selection 7 
When poorly water-soluble drugs were prepared to lyophilized powders for injection, 8 
commonly solubilized methods included adding surfactants and latent solvents, adjusting pH, 9 
inclusion technique, emulsified or micro-emulsification etc. when we design an experiment, in 10 
general, we should consider the operating conditions and procedure, the cost of experiment,  the 11 
kind of equipment to be used and the easiness to carry out the experiment. In this study, according 12 
to physical and chemical properties of GB and characteristics of lyophilized powders, adding 13 
surfactants and adjusting pH were chosen to increase the solubility of GB because these two 14 
methods are easy to fulfill, efficiency in cost and only HPLC instrument is used for experiments, 15 
the other methods of increasing the solubility of GB will be discussed in the future. 16 
Surfactants for injection provided by FDA  include Tween 80, Tween 20, Tween 40, 17 
Poloxamer 188, Cremophor EL, etc. The concentration of the above surfactants were mixed with 18 
2mg GB, respectively, then 1 mL water for injection was added, ultrasonic processing was carried 19 
out for 10 minutes. Clarities of the obtained solution containing Poloxamer 188 or Cremophor EL 20 
were better than the others. It found that moulds produced easily in the Poloxamer 188 solution. 21 
So the Cremophor EL was more suitable, and its safe dose was large（15）.  22 
GB was soluble and stable in concentrated acid, but poorly soluble in weakly acid solution. In 23 
weakly alkaline solution, its lactone rings occurred partial hydrolysis, with the increase of pH, the 24 
more lactone rings opened. From injection aspects to consider, it was suitable to adjust the pH of 25 
GB solution to be acidulous or neutral. The solution (which consisted of PEG 400, Cremophor EL 26 
and water) pH value was around 6.0,. Na2CO3, NaHCO3, phosphate, meglumine, L-arginine, etc. 27 
could be used as the basic pH adjusting agents. L-arginine played an important therapeutic effect 28 
on atherosclerosis, which could promote vasodilation and angiogenesis, as well as inhibit the 29 
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aggregation of platelets and granulocytes（16）. Therefore, L-arginine was chosen as the pH 1 
adjusting agent. 2 
Excipient Screening 3 
The desired appearance of lyophilized powder should be an intact and porous cake structure. 4 
Furthermore, the color should be uniform. In order to obtain a better appearance, some excipients 5 
were added into API to provide a lyophilized skeleton. The following five excipients were used in 6 
this experiment: glucose, lactose, mannitol, dextran 20 and sucrose. The above excipients were 7 
separately added in the PEG 400 and Cremophor EL solution, and the dosage of each excipient 8 
was 6% (g/mL). Then solution appearance and lyophilized product appearances of above 9 
obtained solutions were compared, and the results were shown in Fig.3 and Table 2. By 10 
comprehensive comparison, mannitol as the excipient was the best because the structure by 11 
mannitol as excipient is intact and porous, that means there is no defect (no collapse, no crack on 12 
the surface, no shrink, no spray phenomenon and no collapse at the bottom etc.). 13 
 14 
Table 2 Screening results of five excipients 15 
excipients solution 
appearance 
after standing for 12 h lyophilized product 
appearances 
glucose clear and 
transparent 
clear and transparent serious collapse on one side 
lactose clear and 
transparent 
clear and transparent slight collapse and cracks on the 
surface 
mannitol clear and 
transparent 
clear and transparent intact and porous cake structure 
dextran 20 clear and 
transparent 
precipitation of crystals after 
8 h 
shrinking into a huddle 
sucrose clear and 
transparent 
precipitation of crystals after 
4 h 
collapse near the bottom, forming 
an inverted circular table  
 16 
Formulation Screening by Orthogonal Design  17 
After the determination of solubilization methods and excipients, the formulation of GB 18 
lyophilized powder for injection was screened by orthogonal design. The following four items 19 
were as investigation factors: A-PEG 400 concentration (mL/mL); B-Cremophor EL concentration 20 
(mL/mL); C-mannitol concentration (g/mL); D-solution pH. GB content in the prepared solution 21 
before freeze-drying and its reconstitution time after freeze-drying were as two evaluation indexes. 22 
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The GB content was determined through external standard method of HPLC, building a L9(34) 1 
orthogonal table. 2 
Freeze Drying Process Optimization of GB Lyophilized Powder for Injection 3 
Determination of Glass Transition Temperature of Maximally Freeze-concentrated Solution 4 
In the freeze-drying process, three stages are included, they are freezing, primary drying and 5 
secondary drying. In the freezing stage, the lowest temperature could be confirmed on the basis of 6 
freezing point (including eutectic temperature or glass transition temperature), and the highest 7 
temperature during the primary drying was confirmed on the basis of collapse temperature. 8 
Material freezing point is usually determined through electric resistance method, freeze-drying 9 
microscope observation method and differential scanning calorimetry（17）. 10 
According to the optimized formulation, the GB solution was prepared and the vials with GB 11 
solution were placed on the shelves of freeze drier (Shanghai Tofflon Co., Ltd., China). Two 12 
electrodes of the digital multi-meter were fixed on both sides in a beaker, and the solution 13 
temperature was determined by temperature probes of the freeze drier. Electric resistances of GB 14 
solution and corresponding temperatures were recorded as shown in Table 3. Then the 15 
temperature-resistance curve was obtained from data directly and data by regression(shown in Fig. 16 
4), the temperature at the maximum curvature was the freezing point. The fitted curve was R =17 
a × 𝑒𝑏×𝑇(𝑤ℎ𝑒𝑟𝑒 𝑎 = 0.225, 𝑏 = −0.102) and the computational formula was as following（18）: 18 
                    k=|
R"
(1+R'2)
3
2
|                                         （1） 19 
Where k is the slope of temperature-resistance curve, R is the solution resistance (MΩ), R′ is the 20 
first derivative of the solution resistance, R″ is the second derivative, T is the solution temperature 21 
(℃). 22 
There was not a fixed melting point of GB solution by DSC 204 F1 (Netzsch Geraetebau 23 
GmbH, Germany).Therefore, where the freezing point was the glass transition temperature of 24 
maximally GB freeze-concentrated solution (Tg′). By calculation, the freezing point of GB 25 
solution was -17.6℃, while the freezing point was determined at -16.5℃ through freeze-drying 26 
microscope observation method. We can see the glass transition temperature measured by two 27 
method has a 1℃ difference, it proves that the measured transition temperature has a high 28 
accuracy. In general case, the lowest temperature during the freezing was about 10~20℃ lower 29 
8 
 
than Tg′. Therefore, the lowest freezing temperature was at -45.0℃ to ensure the material being 1 
fully frozen. 2 
 3 
Table 3 Resistances of GB solution and corresponding temperatures 4 
Temperature/℃ 20.4 12.5 6.1 -0.2 -6.6 -12.3 -16.1 -20.4 -26.1 
Electric 
resistance/MΩ 
0.02 0.09 0.15 0.24 0.38 0.64 0.98 2.3 3.24 
 5 
 6 
Determination of Collapse Temperature 7 
During primary drying, if the product temperature is higher than the collapse temperature, the 62 
amorphous material will undergo viscous flow, resulting in loss of the pore structure obtained by 63 
freezing, which is defined as the collapse phenomenon by Pikal and Shah（19）. Collapsed dried 64 
products generally have a high residual water content and lengthy reconstitution times and may 65 
also present a loss of functional properties. Moreover, in the pharmaceutical industry, collapse is a 66 
normally cause for rejection of the vials due to the lack of material elegance. Since a small 67 
variation of temperature can greatly modify the primary drying time as well as the dried product 68 
structure, an accurate determination of the collapse temperature is critical for the process 69 
optimization（20）, the Freeze dry microscope usually is used for measuring collapse temperature. 70 
Collapse temperature of GB lyophilized powder for injection was determined by the FDCS 71 
196 freeze-drying microscope (Linkam Scientific Instruments Ltd., UK). 2 μL GB solution was 72 
taken and dropped between two glass cover slips. Then the freeze-drying stage was sealed, and an 73 
appropriate multiple objective was used to observe the solution. The solution was cooled from 74 
room temperature to -45.0 ℃ at 10.0 ℃/min, then the freeze-drying stage was moved to find the 75 
edge of the frozen solution, and the pressure in the stage maintained at about 20 Pa. Slow heating 76 
was followed, the movement of sublimation interface was observed, to judge at what temperature 77 
it began to collapse and collapsed completely, respectively. During -45.0℃ to -15.0℃, the 78 
sublimation interface moved from the edge of the glass slide to the center, there was a very clear 79 
sublimation interface between the drying zone and freeze zone. And at-14.0℃,  the sublimation 80 
interface became not clear and there was a small quantity of viscous flow, resulting in loss of the 81 
pore structure, meaning -14.0℃  was the temperature of the onset of collapse. When the 82 
temperature increased to -13.0℃,  the more viscous flow happened near the sublimation interface, 83 
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judging that -13.0℃ was the full collapse temperature. Heating up continually, much more 1 
viscous flow happened, and all were shown in Fig. 5.Hence, the highest temperature of primary 2 
drying was below -14.0℃. 3 
Optimization of the Freeze-drying Process by Orthogonal Design 4 
Firstly, various factors influencing GB lyophilized powder quality were confirmed from 5 
preliminary experiments, then freeze-drying process was optimized by orthogonal design. The 6 
following four items were as investigation factors: I: freezing temperature, cooling rate and 7 
duration; II: temperature changes during the primary drying, with gradient heating at 0.1 ℃/min; 8 
III: the primary drying time and pressure; IV: the secondary drying temperature and pressure. 9 
Appearance yield and residual water content were as two evaluation indexes, building a L9(34) 10 
orthogonal table. Residual water content was determined by V 20 Karl Fischer (METTLER 11 
TOLEDO, Switzerland). Qualified appearance criterions: it should be an intact and porous cake 12 
structure (no collapse, no crack on the surface, no shrink, no spray phenomenon and no collapse at 13 
the bottom etc.), without significant volume changes before and after lyophilization（21）. 14 
RESULTS AND DISCUSSIONS  15 
Optimized Formulation  16 
The formulation was optimized by an orthogonal design using the software SPSS 19.0. Factor 17 
levels are shown in Table 4, orthogonal results shown in Table 5 and variance analysis results 18 
shown in Table 6 and Table 7. For the intuitively range analysis of GB content and reconstitution 19 
time in Table 5, the range values represented the influence order of the factors. Therefore, 20 
according to the range values in Table 5, the order of four factors for GB content was D＞B＞A＞21 
C (A: PEG 400 concentration (mL/mL); B: Cremophor EL concentration (mL/mL); C: mannitol 22 
concentration (g/mL); D: solution pH). As for the evaluation index of GB content, the higher mean 23 
value under one factor (A, B, C, D) was required, so D1B2A1C1 was chosen as the optimized 24 
formulation. Similarly, for the reconstitution time of GB lyophilized powder, the influence order 25 
of the factors was B＞A＞D＞C. But the shorter reconstitution time was better, so B3A3D3C1 or 26 
B3A3D3C2 was chosen as the optimized formulation. 27 
As shown in Table 6, through the variance analysis of GB content, only factor D had a 28 
significant influence (p＜0.01), obtaining the highest GB content when factor D in level 1 in Table 29 
5(The GB content increased from 2.5×10-4 mol/L(0.106mg/ml) to 1.914 30 
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(2×(94.7%+96.2%+95.8%)/3)mg/ml ). As shown in Table 7, factor A, B, D had significant effects 1 
on GB lyophilized powder reconstitution time. And in Table 5, when factor A and B were in level 2 
3, the reconstitution time was the shortest. On both GB content and reconstitution time respects by 3 
the variance analyses in Table 6 and Table 7, factor C had no significant effect on measurements. 4 
But the amount of mannitol was chosen 8% (g/mL), the obtained GB lyophilized powder was the 5 
most intact and porous by comparing 6% (g/mL) and 10% (g/mL). Through comprehensive 6 
analyses of the two evaluation indexes, the optimized formulation was D1B3A3C2, i.e. pH at 6.5, 7 
Cremophor EL in an amount of 16% (mL/mL), PEG 400 in an amount of 9% (mL/mL), and 8 
mannitol in an amount of 8% (g/mL). 9 
Table 4 Factor levels 10 
levels 
factors 
A/% B/% C/% D 
1 5 8 6 6.5 
2 7 12 8 7.0 
3 9 16 10 7.5 
 11 
Table 5 Orthogonal design results of formulation screening 12 
No.                     levels                      evaluation indexes 
  A B C D GB 
content/% 
reconstitution 
time /s 
 1 1 1 1 1 94.7 61 
 2 1 2 2 2 86.6 58 
 3 1 3 3 3 36.0 48 
 4 2 1 2 3 36.8 52 
 5 2 2 3 1 96.2 55 
 6 2 3 1 2 87.2 48 
 7 3 1 3 2 85.3 54 
 8 3 2 1 3 38.3 46 
 9 3 3 2 1 95.8 45 
 
GB contents 
mean 1 72.433 72.267 73.400 95.567   
mean 2 73.400 73.700 73.067 86.367   
mean 3 73.133 73.000 72.500 37.033   
Range 0.967 1.433 0.900 58.534   
 
reconstitution 
time 
mean 1 55.667 55.667 51.667 53.667   
mean 2 51.667 53.000 51.667 53.333   
mean 3 48.333 47.000 52.333 48.667   
Range′ 7.334 18.667 0.666 5.000   
 13 
11 
 
 1 
Table 6 Variance analysis results of GB contents 2 
sources of 
variance 
sum of square 
of deviations 
degree of 
freedom 
F ratio F critical 
value 
P value 
A 1.496 2 1.205 19.000  
B 3.082 2 2.481 19.000  
D 5944.569 2 4786.287 99.000 ＜0.01 
（C(error) 1.242 2 1.000   
Note: If F ratio> F critical value, P <0.01, representing the difference was significant. The effect of 3 
C (mannitol concentration )on GB content could be neglected, and its range value in Table 5 was 4 
minimum, so the factor C was chosen as error term. 5 
 6 
Table 7 Variance analysis results of GB lyophilized powder reconstitution time 7 
sources of 
variance 
sum of square 
of deviations 
degree of 
freedom 
F ratio F critical 
value 
P value 
A 80.889 2 90.989 19.000 ＜0.05 
B 118.222 2 132.983 19.000 ＜0.05 
D 46.889 2 52.744 19.000 ＜0.05 
C(error) 0.889 2    
Note: If F ratio> F critical value, P <0.01, representing the difference was significant. The effect of 8 
C (mannitol concentration ) on reconstitution time could be neglected, and its range value in Table 9 
5 was minimum, so the factor C was chosen as error term. 10 
 11 
Confirmation of GB Solution Preparation Process 12 
GB stability is affected by GB adding order, preparing GB solution temperature, amount of 13 
activated carbon and its adsorption time experiments. For example, the order of adding GB API 14 
will affect the transparent time of mixed solution; high temperature of preparing GB solution will 15 
cause the GB decompose; the over amount of active carbon added and more adsorption time of 16 
active carbon will cause the GB content decrease. So, GB adding order, preparing GB solution 17 
temperature, amount of activated carbon and its adsorption time experiments were set up one 18 
factor at a time to study their effects on GB stability. GB solution preparation process was 19 
confirmed as followings: 2.0 mg/mL GB was taken and added into the mixed solvent of 16% 20 
(mL/mL) Cremophor El and 9% (mL/mL) PEG 400, via ultrasonic treatment for 10 minutes. Then 21 
prescribed water for injection were added in it under electromagnetic stirring, and 8% (g/mL) 22 
mannitol was added the obtained solution, L-arginine was used to adjust the pH at 6.5. And 0.05% 23 
12 
 
(g/mL) activated carbon was added into the above solution, then under electromagnetic 1 
stirring(1000 r/min) for 35 minutes at 40.0℃, which was filtered through 0.22 μm PVDF 2 
membrane, finally filled and freeze-dried. 3 
Optimized Freeze-drying Parameters 4 
Through above, freeze-drying parameter optimization was carried out with SPSS 19.0 using 5 
an orthogonal design . Factor levels are shown in Table 8, orthogonal design results are shown in 6 
Table 9, and variance analysis results are shown in Table 10 and Table 11. For the intuitively range 7 
analysis of appearance yield and residual water in Table 9, the range values represented the 8 
influence order of factors. According to the range values in Table 9, considering the appearance 9 
yields, the influence order of the factors was I>II> III> IV (I: freezing temperature, cooling rate 10 
and duration; II: temperature changes during the primary drying, with gradient heating at 0.1 ℃11 
/min; III: the primary drying time and pressure; IV: the secondary drying temperature and 12 
pressure). As for the evaluation index of appearance yield, the higher mean value under one factor 13 
(I, II, III, IV) was required, so I1II3III1IV1 was chosen as the optimized freeze-drying parameters. 14 
Similarly, for the residual water content, the order of the factors was II> IV > I > III. Since  the 15 
lower residual water content of GB lyophilized powder the better,  II3IV3 I1III3 was chosen as the 16 
optimized freeze-drying parameters. 17 
As shown in Table 10, through the variance analysis of appearance yields, the factor I and II 18 
had significant effects (P value <0.05). And in Table 9, when factor I was in level 1 and factor II in 19 
level 3, the appearance yield was the highest. As shown in Table 11, factor II and IV had 20 
significant effects on the residual water content. When factor II was in level 3 and factor IV in 21 
level 3, the residual water content of GB lyophilized powder was the lowest. On both appearance 22 
yield and residual water content respects, factor III had no significant effects. In fact, it is well 23 
known that shorter drying time can shorten the whole freeze-drying cycle and improve the 24 
productivity for enterprises, so III1 (12h, 10 Pa) was chosen as the duration of primary drying. 25 
Based on the above considerations, I1 II3 III1 IV3 was the optimized freeze-drying parameters. 26 
Table 8 Factor levels 27 
levels 
factors 
I II III IV 
1 -45.0℃,0.5 ℃/min,2 h -45.0℃→ -15.0℃ 12 h,10 Pa 20.0℃,20 Pa 
2 -45.0℃,1.0 ℃/min,2 h -45.0℃→-30.0℃ 15 h,10 Pa 20.0℃,50 Pa 
13 
 
-30.0℃→-15.0℃ 
3 -45.0℃,2.0℃/min,2 h -45.0℃→-25.0℃ 
-25.0℃→-15.0℃ 
18 h,10 Pa 20.0℃,80 Pa 
 1 
 2 
Table 9 Orthogonal design results of freeze-drying process 3 
 No. factors evaluation indexes 
  I II III IV appearance 
yield/% 
residual water 
content/% 
 1 1 1 1 1 96.2 3.2 
 2 1 2 2 2 98.3 2.4 
 3 1 3 3 3 99.6 1.2 
 4 2 1 2 3 90.6 2.6 
 5 2 2 3 1 95.7 2.9 
 6 2 3 1 2 97.2 1.8 
 7 3 1 3 2 87.5 3.0 
 8 3 2 1 3 93.9 2.3 
 9 3 3 2 1 94.2 2.5 
appearance 
yield 
mean 1 98.033 91.433 95.767 95.367   
mean 2 94.500 95.967 94.367 94.333   
mean 3 91.867 97.000 94.267 94.700   
Range 6.166 5.567 1.500 1.034   
residual 
water 
content 
mean 1 2.267 2.933 2.433 2.867   
mean 2 2.433 2.533 2.500 2.400   
mean 3 2.600 1.833 2.367 2.033   
Range′ 0.333 1.100 0.133 0.834   
 4 
Table 10 Variance analysis results of appearance yields 5 
sources of 
variance 
sum of square 
of deviations 
degree of 
freedom 
F ratio F critical 
value 
P value 
I 57.447 2 34.880 19.000 <0.05 
II 52.607 2 31.941 19.000 <0.05 
III 4.220 2 2.562 19.000  
IV(error) 1.647 2    
Note: If F ratio> F critical value, P <0.01, representing the difference was significant. The range 6 
value of factor IV in Table 9 on appearance yields was minimum, so it was chosen as error term. 7 
 8 
Table 11 Variance analysis results of residual water content 9 
sources of 
variance 
sum of square 
of deviations 
degree of 
freedom 
F ratio F critical 
value 
P value 
14 
 
I 0.167 2 6.185 19.000  
II 1.860 2 68.889 19.000 <0.05 
IV 1.047 2 38.778 19.000 <0.05 
III(error) 0.027 2    
Note: If F ratio> F critical value, P <0.01, representing the difference was significant. The range 1 
value of factor III in Table 9 on residual water content was minimum, so it was chosen as error 2 
term. 3 
 4 
Verification of Lyophilization Process 5 
According to the previously optimized process, three batches of 300 mL GB solution were 6 
prepared and filled into 7 mL vials, and each vial contained 2 mL solution. These 100 vials were 7 
lyophilized in accordance with the optimized freeze-drying parameters, with the freeze-drying 8 
cycle of 20.7 hours. All products were intact and porous, the mean reconstitution time was (41±5) 9 
seconds, and the mean residual water content was (1.18±0.14)%. It showed that the optimized 10 
formulation and freeze-drying process could meet the specifications of lyophilized powder for 11 
injection, and with a good reproducibility.  12 
Effects of Annealing on Lyophilization Rate and Product Quality 13 
Some researches reported that annealing could improve lyophilization rate and shorten the 14 
freeze-drying cycle（22,23）. Hence, experiments were carried out to study the effects of annealing 15 
on lyophilization rate and product quality. The frozen solution was heated to above the eutectic 16 
temperature or glass transition temperature, but below the melting temperature held for a specified 17 
duration and then frozen again. In the experiments, GB solution has a glass transition temperature 18 
of -17.6℃, so the annealing temperature was set as two different temperatures of -14.5℃ and 19 
-8.0℃. 20 
Annealing at -14.5℃ 21 
At normal atmospheric pressure, the GB solution was frozen from room temperature to 22 
-45.0℃, and then immediately heated to -14.5℃. This temperature was maintained constant for 23 
one hour, so that the lyophilization process continued following the above mentioned optimized 24 
freeze-drying parameters. By annealing at -14.5℃, the period of primary drying was shortened of 25 
about three hours, so that the whole cycle was 21.7 hours long. Compared to the GB lyophilized 26 
powder without annealing, the products annealed at -14.5℃ were looser, and the apertures were 27 
larger, even showing some cavities, and  slight collapse occurred for about 1 percent of the 28 
15 
 
material, as shown in Fig. 6. In terms of residual water content, GB content, related substances and 1 
pH, both of the two had no significant differences. 2 
 3 
Annealing at -8.0℃ 4 
Like the above annealing treatment, another batch of GB solution was annealed at -8.0℃ for 5 
one hour. The period of primary drying was shortened to about three hours, the freeze-drying cycle 6 
was 22.2 hours and the whole process parameters was automatically recorded by the lyophilizer. 7 
GB lyophilized powder in all vials shrinked up severely and had difficult in reconstitution, shown 8 
in Fig. 7. Compared to the GB lyophilized powder without annealing, the products annealed at 9 
-14.5℃ had no significant differences in terms of residual water content, GB content, related 10 
substances and pH. 11 
To find the reason of annealing collapse at -14.5℃ and -8.0℃, decreasing freeze temperature 12 
and extending its time, decreasing the highest temperature and pressure of the primary drying 13 
measures were taken, only decreasing the highest temperature of the primary drying was helpful to 14 
improve the collapse. It could be deduced that the annealing treatment might improve the collapse 15 
temperature because of the changes of ice crystal morphology and size distribution. Thus, 16 
qualified GB lyophilized powder for injection could be obtained according to the optimized 17 
process, without annealing. 18 
CONCLUSION 19 
In this paper, the optimal formulation of GB lyophilized powder for injection was determined 20 
alongside  with the optimised conditions for the complete formulation process. Firstly,  solvent, 21 
solubilizer, excipient and pH screen were screened, PEG 400 in an amount of 9% (mL/mL), 22 
Cremophor EL in an amount of 16% (mL/mL), mannitol in an amount of 8% (g/mL) and pH at 6.5 23 
were determined to make the solubility of GB improved of more than 18 times (from 0.106mg/ml 24 
to 1.914 mg/ml). Secondly, the preparing process was carried out by using a one factor at a time 25 
experimental design; thirdly, by orthogonal design, the optimized formulation was obtained. The 26 
optimized operation schedule for the process was: freezing from room temperature to -45.0℃ at 27 
0.5 ℃/min,  then holding for 2 hours; in the primary drying stage, heating the temperature from 28 
-45.0℃to ﹣25.0℃ at 0.1℃/min, and then holding for 3 hours; heating the temperature from 29 
-25.0℃ to﹣15.0℃ at 0.1℃/min, and holding for 4 hours; in the whole primary drying stage 30 
16 
 
the chamber pressure was kept at 10 Pa; in the secondary drying stage, heating the 1 
temperature from -15.0℃ to 20.0℃ at 1℃/min, and holding for 4 hours, with the chamber 2 
pressure kept to 80 Pa. Then, the verification batch experiments have been carried out according to 3 
the above optimized protocol. A very satisfactory quality for GB lyophilized power for injection 4 
was achieved. Furthermore, post-freezing annealing process analysis has been carried out. The 5 
relevant discovery was that annealing is not beneficial for the processsince it did not allow to 6 
reduce the freeze-drying cycle and, what was worse, it caused some collapse on the material. 7 
Therefore, a complete process of formulation preparation of GB lyopilized power for injectionhas 8 
been given. This study would provide references for optimization technology of GB lyophilized 9 
powder for injection. 10 
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 20 
Thanks for your helpful suggestion to improve the paper. We have corrected the misunderstood 21 
according to your comments. On original page 6 and page 7, changed from “dissolution status” to 22 
“solution appearance”, and from ”lyophilized solution appearances” to “lyophilized product 23 
appearance”. 24 
Fig.1 The structure of Ginkgolide B 
 
Fig. 2 The standard curve between concentrations and peak areas of GB 
 
Fig. 3 Lyophilized product appearances of five excipients 
 
Fig. 4 The temperature-resistance curve of GB solution 
 
Fig. 5 Collapse process of GB lyophilized powder: a(at-15℃),b( at-14℃),c(at-13℃),d(at-12℃). 
 
Fig. 6 The left vial was the appearance of GB lyophilized powder without annealing 
 
Fig. 7 The left vial was the appearance of GB lyophilized powder without annealing 
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